The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
Abstract
Despite years of research and hundreds of reports on tumor markers in oncology, the number of markers that have emerged as clinically useful is pitifully small. Often, initially reported studies of a marker show great promise, but subsequent studies on the same or related markers yield inconsistent conclusions or stand in direct contradiction to the promising results. It is imperative that we attempt to understand the reasons that multiple studies of the same marker lead to differing conclusions. A variety of methodologic problems have been cited to explain these discrepancies. Unfortunately, many tumor marker studies have not been reported in a rigorous fashion, and published articles often lack sufficient information to allow adequate assessment of the quality of the study or the generalizability of study results. The development of guidelines for the reporting of tumor marker studies was a major recommendation of the National Cancer Institute-European Organisation for Research and Treatment of Cancer (NCI-EORTC) First International Meeting on Cancer Diagnostics in 2000. As for the successful CONSORT initiative for randomized trials and for the STARD statement for diagnostic studies, we suggest guidelines to provide relevant information about the study design, preplanned hypotheses, patient and specimen characteristics, assay methods, and statistical analysis methods. In addition, the guidelines suggest helpful presentations of data and important elements to include in discussions. The goal of these guidelines is to encourage transparent and complete reporting so that the relevant information will be available to others to help them to judge the usefulness of the data and understand the context in which the conclusions apply.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While making revisions, conscious efforts were made to harmonize our recommendations with other reporting guidelines, and where possible we chose the same or similar wording for items [37,39,41,45,46].”
From Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement (2015) · cites this paper as [37]
In the citing paper
“These items have been identified as important in several well-known guidelines for reporting of clinical research [4],[38]–[41].”
From Reporting and Methods in Clinical Prediction Research: A Systematic Review (2012) · cites this paper as [4]
In the citing paper
“Most guidelines, such as the STROBE guidelines for the reporting of observational studies or the REMARK guidelines for tumour marker prognostic studies, specifically advise investigators to report both unadjusted results (i.e., from univariable analysis, yielding the association of each candidate predictor with the outcome) and adjusted results (i.e., from a multivariable analysis) [4],[38],[63].”
From Reporting and Methods in Clinical Prediction Research: A Systematic Review (2012) · cites this paper as [4]
In the citing paper
“However, none of these guidelines are entirely appropriate for prediction model studies.”
From Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD): The TRIPOD Statement (2015) · cites this paper as [37]
In the citing paper
“However, the focus of the REMARK checklist is primarily on prognostic factors and not prediction models, whereas the GRIPS statement is aimed at risk prediction using genetic risk factors and the specific methodological issues around handling large numbers of genetic variants.”
From Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD): The TRIPOD Statement (2015) · cites this paper as [37]
Citations
Cites
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
Moher, D., Schulz, K. F., & Altman, D. G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04337-3 · Cited by 5,373
Self-citationMoher, D., Cook, D. J., Eastwood, S., Olkin, I., Rennie, D., & Stroup, D. F. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04149-5 · Cited by 4,826
The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration
Altman, D. G., Schulz, K. F., Moher, D., Egger, M., Davidoff, F., Elbourne, D., Gøtzsche, P. C., Lang, T., & for the CONSORT Group (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-8-200104170-00012 · Cited by 3,835
Self-citationTowards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative.
Bossuyt, P. M., Reitsma, J. B., Bruns, D. E., Gatsonis, C. A., Glasziou, P. P., Irwig, L. M., Lijmer, J. G., Moher, D., Rennie, D., de Vet, H. C. W., et al. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-1-200301070-00010 · Cited by 3,219
Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative
Bossuyt, P. M., Reitsma, J. B., Bruns, D. E., Gatsonis, C. A., Glasziou, P. P., Irwig, L. M., Lijmer, J. G., Moher, D., Rennie, D., & de Vet, H. C. W. (2003) · BMJ · doi:10.1136/bmj.326.7379.41 · Cited by 3,215
Moher, D. (2001) · JAMA · doi:10.1001/jama.285.15.1987 · Cited by 2,545
Systematic Reviews in Health Care : Meta-Analysis in Context
Egger, M., Smith, G. D., & Altman, D. G. (2000) · Cited by 2,312
Self-citationDangers of Using "Optimal" Cutpoints in the Evaluation of Prognostic Factors
Altman, D. G., Lausen, B., Sauerbrei, W., & Schumacher, M. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.11.829 · Cited by 1,143
Self-citationThe Risk of Determining Risk with Multivariable Models
Concato, J., Feinstein, A. R., & Holford, T. R. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-3-199302010-00009 · Cited by 1,129
Cited by
Sorted by citations
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).
Klionsky, D. J., Abdelmohsen, K., Abe, A., Abedin, M. J., Abeliovich, H., Acevedo Arozena, A., Adachi, H., Adams, C. M., Adams, P. D., Adeli, K., et al. (2016) · Autophagy · doi:10.1080/15548627.2015.1100356 · Cited by 5,894
Moons, K. G. M., Altman, D. G., Reitsma, J. B., Ioannidis, J. P. A., Macaskill, P., Steyerberg, E. W., Vickers, A. J., Ransohoff, D. F., & Collins, G. S. (2015) · Annals of Internal Medicine · doi:10.7326/m14-0698 · Cited by 5,147
Self-citationGuidelines for the use and interpretation of assays for monitoring autophagy
Klionsky, D. J., Abdalla, F. C., Abeliovich, H., Abraham, R. T., Acevedo-Arozena, A., Adeli, K., Agholme, L., Agnello, M., Agostinis, P., Aguirre-Ghiso, J. A., et al. (2012) · Autophagy · doi:10.4161/auto.19496 · Cited by 3,996
Collins, P. G. S., Reitsma, J. B., Altman, D. G., & Moons, K. G. M. (2015) · British Journal of Cancer · doi:10.1038/bjc.2014.639 · Cited by 3,315
Self-citationCollins, G. S., Reitsma, J. B., Altman, D. G., & Moons, K. G. M. (2015) · Annals of Internal Medicine · doi:10.7326/m14-0697 · Cited by 3,267
Self-citationGuidelines for the use and interpretation of assays for monitoring autophagy (4th edition) 1
Klionsky, D. J., Abdel-Aziz, A. K., Abdelfatah, S., Abdellatif, M., Abdoli, A., Abel, S., Abeliovich, H., Abildgaard, M. H., Abudu, Y. P., Acevedo-Arozena, A., et al. (2021) · Autophagy · doi:10.1080/15548627.2020.1797280 · Cited by 2,897
Denkert, C., von Minckwitz, G., Darb-Esfahani, S., Lederer, B., Heppner, B. I., Weber, K. E., Budczies, J., Huober, J., Klauschen, F., Furlanetto, J., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30904-x · Cited by 2,157
Collins, G. S., Reitsma, J. B., Altman, D. G., & Moons, K. (2015) · BMC Medicine · doi:10.1186/s12916-014-0241-z · Cited by 1,927
Self-citationLoi, S., Sirtaine, N., Piette, F., Salgado, R., Viale, G., Eenoo, F. V., Rouas, G., Francis, P. A., Crown, J. P., Hitre, E., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.0902 · Cited by 1,658
Fukuoka, M., Wu, Y.-L., Thongprasert, S., Sunpaweravong, P., Leong, S.-S., Sriuranpong, V., Chao, T.-Y., Nakagawa, K., Chu, D.-T., Saijo, N., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.4235 · Cited by 1,581
Reducing waste from incomplete or unusable reports of biomedical research
Glasziou, P., Altman, D. G., Bossuyt, P., Boutron, I., Clarke, M., Julious, S., Michie, S., Moher, D., & Wager, E. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62228-x · Cited by 1,319
Self-citationLoi, S., Michiels, S., Salgado, R., Sirtaine, N., José, V., Fumagalli, D., Kellokumpu‐Lehtinen, P., Bono, P., Kataja, V. V., Desmedt, C., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu112 · Cited by 1,254
Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis
Sia, D., Villanueva, A., Friedman, S. L., & Llovet, J. M. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.11.048 · Cited by 1,181
Imaging biomarker roadmap for cancer studies
O'Connor, J. P. B., Aboagye, E. O., Adams, J. E., Aerts, H. J. W. L., Barrington, S. F., Beer, A. J., Boellaard, R., Bohndiek, S. E., Brady, M., Brown, G., et al. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.162 · Cited by 1,091
Self-citationUse of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
Simon, R. M., Paik, S., & Hayes, D. F. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp335 · Cited by 1,040
Denkert, C., von Minckwitz, G., Brase, J. C., Sinn, B. V., Gade, S., Kronenwett, R., Pfitzner, B. M., Salat, C., Loi, S., Schmitt, W., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.1967 · Cited by 1,033
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration
Altman, D. G., McShane, L. M., Sauerbrei, W., & Taube, S. E. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001216 · Cited by 1,034
Self-citationJohnson, N. A., Slack, G. W., Savage, K. J. J., Connors, J. M., Ben‐Neriah, S., Rogić, S., Scott, D. W., Tan, K. L., Steidl, C., Sehn, L. H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.0985 · Cited by 975
Sharing Detailed Research Data Is Associated with Increased Citation Rate
Piwowar, H. A., Day, R. S., & Fridsma, D. B. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000308 · Cited by 881
Collins, G. S., Reitsma, J. B., Altman, D. G., & Moons, K. G. M. (2015) · British Journal of Surgery · doi:10.1002/bjs.9736 · Cited by 889
Self-citationOvarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies
Köbel, M., Kalloger, S. E., Boyd, N., McKinney, S., Mehl, E., Palmer, C., Leung, S., Bowen, N. J., Ionescu, D. N., Rajput, A., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050232 · Cited by 814
Nielsen, T. O., Parker, J. S., Leung, S. C. Y., Voduc, D. K., Ebbert, M., Vickery, T. L., Davies, S. R., Snider, J., Stijleman, I. J., Reed, J. P., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1282 · Cited by 825
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
Ahmed, A. A., Etemadmoghadam, D., Temple, J., Lynch, A. G., Riad, M., Sharma, R. N., Stewart, C. J. R., Fereday, S., Caldas, C., DeFazio, A., et al. (2010) · The Journal of Pathology · doi:10.1002/path.2696 · Cited by 815
Collins, G. S., Reitsma, J. B., Altman, D. G., & Moons, K. G. M. (2015) · Circulation · doi:10.1161/circulationaha.114.014508 · Cited by 793
Self-citationAssociation between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients
Ali, H. R., Provenzano, E., Dawson, S., Blows, F. M., Liu, B., Shah, M., Earl, H. M., Poole, C. J., Hiller, L., Dunn, J., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu191 · Cited by 789
Identification of metastasis-related microRNAs in hepatocellular carcinoma
Budhu, A., Jia, H., Forgues, M., Liu, C., Goldstein, D., Lam, A., Zanetti, K. A., Ye, Q., Qin, L., Croce, C. M., et al. (2008) · Hepatology · doi:10.1002/hep.22160 · Cited by 697
Exosomal miR-1290 and miR-375 as Prognostic Markers in Castration-resistant Prostate Cancer
Huang, X., Yuan, T., Liang, M., Du, M., Xia, S., Dittmar, R. L., Wang, D., See, W. A., Costello, B. A., Quevedo, F., et al. (2014) · European Urology · doi:10.1016/j.eururo.2014.07.035 · Cited by 681
Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA
Thierry, A. R., Mouliere, F. C., Messaoudi, S. E., Mollévi, C., Lopez‐Crapez, E., Rolet, F., Gillet, B., Gongora, C., Dechelotte, P., Robert, B., et al. (2014) · Nature Medicine · doi:10.1038/nm.3511 · Cited by 687
Prognosis research strategy (PROGRESS) 1: A framework for researching clinical outcomes
Hemingway, H., Croft, P. R., Perel, P., Hayden, J. A., Abrams, K. R., Timmis, A., Briggs, A. H., Udumyan, R., Moons, K. G. M., Steyerberg, E. W., et al. (2013) · BMJ · doi:10.1136/bmj.e5595 · Cited by 698
Self-citationDiagnostic and prognostic implications of microRNA profiling in prostate carcinoma
Fendler, A., Jung, M., Mollenkopf, H., Wagner, I., Stephan, C., Jentzmik, F., Miller, K., Lein, M., Kristiansen, G., & Jung, K. (2009) · International Journal of Cancer · doi:10.1002/ijc.24827 · Cited by 611
Salgado, R., Denkert, C., Campbell, C., Savas, P. S., Nuciforo, P. G., Aura, C. M., de Azambuja, E., Eidtmann, H., Ellis, C. E., Baselga, J. M., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.0830 · Cited by 605
Reporting and Methods in Clinical Prediction Research: A Systematic Review
Bouwmeester, W., Zuithoff, N. P. A., Mallett, S., Geerlings, M. I., Vergouwe, Y., Steyerberg, E. W., Altman, D. G., & Moons, K. G. M. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001221 · Cited by 600
Self-citationRecent developments in meta‐analysis
Sutton, A. J., & Higgins, J. P. T. (2007) · Statistics in Medicine · doi:10.1002/sim.2934 · Cited by 601
Biomarkers of response and resistance to antiangiogenic therapy
Jain, R. K., Duda, D. G., Willett, C. G., Sahani, D. V., Zhu, A. X., Loeffler, J. S., Batchelor, T. T., & Sorensen, A. G. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.63 · Cited by 572
Biosensors for cancer markers diagnosis
Tothill, I. E. (2009) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2009.01.015 · Cited by 558
Biomarker development in the precision medicine era: lung cancer as a case study
Vargas, A. J., & Harris, C. C. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.56 · Cited by 562
Denkert, C., Seither, F., Schneeweiß, A., Link, T., Blohmer, J., Just, M., Wimberger, P., Forberger, A., Tesch, H., Jackisch, C., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00301-6 · Cited by 562
Ogino, S., Chan, A. T., Fuchs, C. S., & Giovannucci, E. L. (2010) · Gut · doi:10.1136/gut.2010.217182 · Cited by 527
Duffy, M. J., van Dalen, A., Haglund, C. H., Hansson, L., Holinski‐Feder, E., Klapdor, R., Lamerz, R., Peltomäki, P., Sturgeon, C., & Topolčan, O. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.03.021 · Cited by 513
Sauerbrei, W., Taube, S. E., McShane, L. M., Cavenagh, M. M., & Altman, D. G. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy088 · Cited by 500
Self-citationBeyond PSA: The Next Generation of Prostate Cancer Biomarkers
Prensner, J. R., Rubin, M. A., Wei, J. T., & Chinnaiyan, A. M. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003180 · Cited by 479
Sotiriou, C. P., & Piccart, M. J. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2173 · Cited by 456
Human Microbiome Fusobacterium Nucleatum in Esophageal Cancer Tissue Is Associated with Prognosis
Yamamura, K., Baba, Y., Nakagawa, S., Mima, K., Miyake, K., Nakamura, K., Sawayama, H., Kinoshita, K., Ishimoto, T., Iwatsuki, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1786 · Cited by 457
Collins, G. S., Reitsma, J. B., Altman, D. G., & Moons, K. G. M. (2015) · European Urology · doi:10.1016/j.eururo.2014.11.025 · Cited by 439
Self-citationVillanueva, A., Hoshida, Y., Battiston, C., Tovar, V., Sia, D., Alsinet, C., Cornellà, H., Liberzon, A., Kobayashi, M., Kumada, H., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.006 · Cited by 448
Rizzardi, A. E., Johnson, A. T., Vogel, R. I., Pambuccian, S. E., Henriksen, J. C., Skubitz, A. P. N., Metzger, G. J., & Schmechel, S. C. (2012) · Diagnostic Pathology · doi:10.1186/1746-1596-7-42 · Cited by 440
Clinical impact of programmed cell death ligand 1 expression in colorectal cancer
Droeser, R. A., Hirt, C., Viehl, C. T., Frey, D. M., Nebiker, C. A., Huber, X., Zlobec, I., Eppenberger‐Castori, S., Tzankov, A., Rosso, R., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.02.015 · Cited by 436
DNA methylation‐based prognosis and epidrivers in hepatocellular carcinoma
Villanueva, A., Portela, A., Sayols, S., Battiston, C., Hoshida, Y., Méndez‐González, J., Imbeaud, S., Letouzé, É., Hernández–Gea, V., Cornellà, H., et al. (2015) · Hepatology · doi:10.1002/hep.27732 · Cited by 434
Mitsuhashi, K., Nosho, K., Sukawa, Y., Matsunaga, Y., Ito, M., Kurihara, H., Kanno, S., Igarashi, H., Naito, T., Adachi, Y., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3109 · Cited by 404
Okadome, K., Baba, Y., Yagi, T., Kiyozumi, Y., Ishimoto, T., Iwatsuki, M., Miyamoto, Y., Yoshida, N., Watanabe, M., & Baba, H. (2018) · Annals of Surgery · doi:10.1097/sla.0000000000002985 · Cited by 393
Collins, G. S., Reitsma, J. B., Altman, D. G., & Moons, K. G. M. (2015) · Annals of Internal Medicine · doi:10.7326/l15-5093-2 · Cited by 493
Self-citationReporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration
Altman, D. G., McShane, L. M., Sauerbrei, W., & Taube, S. E. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-51 · Cited by 378
Self-citationFoekens, J. A., Sieuwerts, A. M., Smid, M., Look, M. P., de Weerd, V., Boersma, A. W. M., Klijn, J. G. M., Wiemer, E. A. C., & Martens, J. W. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803304105 · Cited by 372
Pierga, J., Bidard, F., Mathiot, C., Brain, E. G. C., Delaloge, S., Giachetti, S., de Crémoux, P., Salmon, R. J., Vincent‐Salomon, A., & Marty, M. E. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0030 · Cited by 369
Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer
Janni, W., Rack, B. K., Terstappen, L. W. M. M., Pierga, J., Taran, F., Fehm, T. N., Hall, C. S., de Groot, M. R., Bidard, F., Friedl, T. W. P., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1603 · Cited by 363
Evolution of Translational Omics: Lessons Learned and the Path Forward
Micheel, C., Nass, S. J., & Omenn, G. S. (2013) · Cited by 365
Tan, I. B., Ivanova, T., Lim, K. H., Ong, C. W., Deng, N., Lee, J., Tan, S. H., Wu, J., Lee, M. H., Ooi, C.-H., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.04.042 · Cited by 357
Fehm, T. N., Müller, V., Aktas, B., Janni, W., Schneeweiß, A., Stickeler, E., Lattrich, C., Löhberg, C. R., Solomayer, E. F., Rack, B. K., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1163-x · Cited by 354
Johnson, P. J., Pirrie, S. J., Cox, T. F., Berhane, S., Teng, M. J., Palmer, D. H., Morse, J., Hull, D., Patman, G., Kagebayashi, C., et al. (2013) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-13-0870 · Cited by 360
Prognostic versus predictive value of biomarkers in oncology
Oldenhuis, C. N. A. M., Oosting, S. F., Gietema, J. A., & de Vries, E. G. E. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.03.006 · Cited by 349
Cell-free DNA in the blood as a solid tumor biomarker–a critical appraisal of the literature
Jung, K., Fleischhacker, M., & Rabien, A. (2010) · Clinica Chimica Acta · doi:10.1016/j.cca.2010.07.032 · Cited by 337
Biospecimen Reporting for Improved Study Quality (BRISQ)
Moore, H. M., Kelly, A. B., Jewell, S. D., McShane, L. M., Clark, D. P., Greenspan, R., Hayes, D. F., Hainaut, P. L., Kim, P., Mansfield, E. A., et al. (2011) · Journal of Proteome Research · doi:10.1021/pr200021n · Cited by 339
Self-citationIntestinal Microbiota and Relapse After Hematopoietic-Cell Transplantation
Peled, J. U., Devlin, S. M., Staffas, A., Lumish, M., Khanin, R., Littmann, E. R., Ling, L., Kosuri, S., Maloy, M., Slingerland, J. B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.3348 · Cited by 325
Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia
Rossi, D., Khiabanian, H., Spina, V., Ciardullo, C., Bruscaggin, A., Famà, R., Rasi, S., Monti, S. M., Deambrogi, C., Paoli, L. D., et al. (2014) · Blood · doi:10.1182/blood-2013-11-539726 · Cited by 346
A Hepatocellular Carcinoma 5-Gene Score Associated With Survival of Patients After Liver Resection
Nault, J., de Reyniès, A., Villanueva, A., Caldéraro, J., Rebouissou, S., Couchy, G., Decaens, T., Franco, D., Imbeaud, S., Rousseau, F., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.03.051 · Cited by 336
Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial
Greenhalf, W., Ghaneh, P., Neoptolemos, J. P., Palmer, D. H., Cox, T. F., Lamb, R. F., Garner, E., Campbell, F., Mackey, J. R., Costello, E., et al. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt347 · Cited by 336
Muenst, S. E., Soysal, S. D., Gao, F., Obermann, E. C., Oertli, D., & Gillanders, W. E. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2581-3 · Cited by 338
Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer
Church, D. N., Stelloo, E., Nout, R. A., Valtcheva, N., Depreeuw, J., ter Haar, N. T., Noske, A., Amant, F. C., Tomlinson, I. P. M., Wild, P. J., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju402 · Cited by 337
Hernandez, S. F., López‐Knowles, E., Lloreta, J., Kogevinas, M., Amorós, À., Tardón, A., Carrato, A., Serra, C., Malats, N., & Real, F. X. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1771 · Cited by 334
Collins, P. G. S., Reitsma, J. B., Altman, D. G., & Moons, K. G. M. (2015) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2014.11.010 · Cited by 336
Self-citationTsao, M., Aviel‐Ronen, S., Ding, K., Lau, D., Liu, G., Sakurada, A., Whitehead, M., Zhu, C., Livingston, R. B., Johnson, D. H., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.6953 · Cited by 332
Considerations in the development of circulating tumor cell technology for clinical use
Parkinson, D. R., Dracopoli, N. C., Petty, B. G., Compton, C. C., Cristofanilli, M., Deisseroth, A., Hayes, D. F., Kapke, G. F., Kumar, P. K. M., Lee, J. S. H., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-138 · Cited by 331
Portrait of the PI3K/AKT pathway in colorectal cancer
Danielsen, S. A., Eide, P. W., Nesbakken, A., Guren, T. K., Leithe, E., & Lothe, R. A. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.09.008 · Cited by 336
Luporsi, É., André, F., Spyratos, F., Martin, P., Jacquemier, J. D., Penault-Llorca, F. M., Tubiana-Mathieu, N., Sigal‐Zafrani, B., Arnould, L., Gompel, A., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1837-z · Cited by 316
Dawson, S.-J., Makretsov, N. A., Blows, F. M., Driver, K. E., Provenzano, E., Quesne, J. P. C. L., Baglietto, L., Severi, G., Giles, G. G., McLean, C., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605736 · Cited by 326
Biomarkers and surrogate end points—the challenge of statistical validation
Buyse, M. E., Sargent, D. J., Grothey, A. F., Matheson, A., & de Gramont, A. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.43 · Cited by 320
Domingo, E., Freeman-Mills, L., Rayner, E., Glaire, M., Briggs, S., Vermeulen, L., Fessler, E., Medema, J. P., Boot, A., Morreau, H., et al. (2016) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(16)30014-0 · Cited by 308
Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non–Small Cell Lung Cancer
Dønnem, T., Hald, S. M., Paulsen, E., Richardsen, E. H., Al‐Saad, S., Kilvaer, T. K., Brustugun, O. T., Helland, Å., Lund‐Iversen, M., Poehl, M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1905 · Cited by 316
Baggerly, K., & Coombes, K. R. (2009) · The Annals of Applied Statistics · doi:10.1214/09-aoas291 · Cited by 311
Molecular Classification and Novel Targets in Hepatocellular Carcinoma: Recent Advancements
Hoshida, Y., Toffanin, S., Lachenmayer, A., Villanueva, A., Mínguez, B., & Llovet, J. M. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1247131 · Cited by 317
Dieci, M. V., Mathieu, M. C., Guarneri, V., Conte, P., Delaloge, S., André, F., & Goubar, A. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv239 · Cited by 310
Cullen, J., Rosner, I. L., Brand, T. C., Zhang, N., Tsiatis, A. C., Moncur, J., Ali, A., Chen, Y., Knezevic, D., Maddala, T., et al. (2015) · European Urology · doi:10.1016/j.eururo.2014.11.030 · Cited by 310
Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival
Morris, L. G. T., Riaz, N., Desrichard, A., Şenbabaoğlu, Y., Hakimi, A. A., Makarov, V., Reis-Filho, J. S., & Chan, T. A.-T. (2016) · Oncotarget · doi:10.18632/oncotarget.7067 · Cited by 307
Parkinson, C., Gale, D. G., Piskorz, A., Biggs, H., Hodgkin, C., Addley, H. C., Freeman, S., Moyle, P., Sala, E., Sayal, K., et al. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002198 · Cited by 299
Buteau, J. P., Martin, A. J., Emmett, L., Iravani, A., Sandhu, S., Joshua, A. M., Francis, R. J., Zhang, A. Y., Scott, A. M., Lee, S.-T., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00605-2 · Cited by 296
Cancer immunology—analysis of host and tumor factors for personalized medicine
Ogino, S., Galon, J., Fuchs, C. S., & Dranoff, G. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.122 · Cited by 287
Park, J. E., Kim, D., Kim, H. S., Park, S. Y., Kim, J. Y., Cho, S. J., Shin, J. H., & Kim, J. H. (2019) · European Radiology · doi:10.1007/s00330-019-06360-z · Cited by 301
Prognostic and predictive factors in colorectal cancer
Zlobec, I., & Lugli, A. K. (2008) · Postgraduate Medical Journal · doi:10.1136/jcp.2007.054858 · Cited by 282
Assessment of claims of improved prediction beyond the Framingham risk score.
Tzoulaki, I., Liberopoulos, G., & Ioannidis, J. (2009) · Journal of the American Medical Association (JAMA) · doi:10.1001/jama.2009.1757 · Cited by 281
Shrotriya, S., Walsh, D., Bennani-Baiti, N., Thomas, S., & Lorton, C. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0143080 · Cited by 275
Wolff, A. C., Lazar, A., Bondarenko, I., Garin, A. M., Brincat, S., Chow, L. W. C., Sun, Y. P., Nešković‐Konstantinović, Z., Guimarães, R. C., Fumoleau, P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.3331 · Cited by 280
Bairi, K. E., Haynes, H. R., Blackley, E. F., Fineberg, S., Shear, J., Turner, S., de Freitas, J. R., Sur, D. G., Amendola, L. C., Gharib, M., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00346-1 · Cited by 285
Field, N. M., Cohen, T., Struelens, M. J., Palm, D., Cookson, B., Glynn, J. R., Gallo, V., Ramsay, M. E., Sonnenberg, P., MacCannell, D., et al. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70324-4 · Cited by 261
Dancey, J. E., Dobbin, K. K., Groshen, S. G., Jessup, J. M., Hruszkewycz, A. H., Koehler, M. T., Parchment, R. E., Ratain, M. J., Shankar, L. K., Stadler, W. M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2167 · Cited by 259
Loibl, S., von Minckwitz, G., Schneeweiß, A., Paepke, S., Lehmann, A., Rezai, M., Zahm, D. M., Sinn, H., Khandan, F., Eidtmann, H., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.7876 · Cited by 258
NCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in Oncology
Febbo, P. G., Ladanyi, M., Aldape, K., Marzo, A. M. D., Hammond, M. E. H., Hayes, D. F., Iafrate, A. J., Kelley, R. K., Marcucci, G., Ogino, S., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0137 · Cited by 262
Cancer Therapy–Induced Cardiac Toxicity in Early Breast Cancer
Khouri, M. G., Douglas, P. S., Mackey, J. R., Martín, M., Scott, J. M., Scherrer‐Crosbie, M., & Jones, L. W. (2012) · Circulation · doi:10.1161/circulationaha.112.100560 · Cited by 255
Hepatocellular Carcinoma: Novel Molecular Approaches for Diagnosis, Prognosis, and Therapy
Villanueva, A., Mínguez, B., Forner, A., Reig, M., & Llovet, J. M. (2010) · Annual Review of Medicine · doi:10.1146/annurev.med.080608.100623 · Cited by 252
Non-coding RNAs participate in the regulatory network of CLDN4 via ceRNA mediated miRNA evasion
Song, Y., Sun, J., Zhao, J., Yang, Y., Shi, J., Wu, Z., Chen, X., Gao, P., Miao, Z., & Wang, Z.-N. (2017) · Nature Communications · doi:10.1038/s41467-017-00304-1 · Cited by 252
Panwalkar, P., Clark, J. R., Ramaswamy, V., Hawes, D., Yang, F., Dunham, C. P., Yip, S. S. F., Hukin, J., Sun, Y., Schipper, M. J., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1752-4 · Cited by 250
Metadata
- Authors
- McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- McShane, Lisa M.
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-08-17
- Volume
- 97
- Issue
- 16
- Pages
- 1180-1184
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2096910745
- Cited by
- 2,162
- References
- 46
- Citations by year
- 2026: 112 · 2025: 38 · 2024: 44 · 2023: 42 · 2022: 39 · 2021: 93 · 2020: 100 · 2019: 126 · 2018: 116 · 2017: 127 · 2016: 163 · 2015: 192 · 2014: 167 · 2013: 150 · 2012: 173
- FWCI
- 56.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JNCI Journal of the National Cancer Institute (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Yale University
- Yale Cancer Center
- Cancer Research UK
- Translational Cancer Research Network
- National Cancer Institute (MD 20892, 20892)
- Topics
- Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Epidemiology
- Health Sciences › Medicine › Oncology › Cancer Diagnosis and Treatment
- Keywords
- tumor markers, prognostic factors, reporting guidelines, remarks, reporting quality, methodological discrepancies, research design, assay method, statistical analysis methods, cancer diagnosis, research transparency
- MeSH terms
- Humans, Neoplasms, Research Design, Biomarkers, Tumor, Information Dissemination, Biomedical Research
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
